We are live on ! Find out more

Ardelyx

ARDX

Market cap $976M

3.78 USD

+0.07

1.89%

At close Updated Sep 4, 4:00 PM EDT

Pre-market

After hours

3.76

-0.02

0.53%

1 day

1.89%

5 days

-0.53%

1 month

-24.55%

3 months

-30%

6 months

-43.16%

Year to date

-38.54%

1 year

-42.47%

5 years

170%

10 years

-64.51%

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 489

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 56.3%

Negative 43.8%

Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:

Ardelyx to Participate in Upcoming Investor Conferences

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)

Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)

ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)

NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. The damage came alongside numbers the Company itself called records. Arde.

ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, citing payer utilization-management restrictions -- and shares fell nearly 18% the next session. NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Payer coverage restrictions allegedly cost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on August 7, 2026, when the stock closed at $4.00 after the Company attributed a full-year IBSRELA guidance cut to increased step edits and more stringent prior authorizations.

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates.

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. remains a hold due to near-term execution uncertainty despite strong underlying demand for IBSRELA and a robust long-term opportunity. ARDX's Q2 revenue grew 31% YoY, driven by IBSRELA and XPHOZAH, but payer friction is capping near-term monetization and led to a guidance cut. Management is actively addressing access bottlenecks with expanded reimbursement teams, pharmacy network optimization, and increased sales force to convert demand into realized revenue.

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

Zacks Investment Research

New Strong Sell Stocks for August 7th

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

New Strong Sell Stocks for August 7th

Zacks Investment Research

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Ardelyx (ARDX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year ago.

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

See News Rankings

Price charts implemented using Lightweight Charts™